BeOne’s Brukinsa cuts risk of progression or death by 43% in frontline mantle cell lymphoma Phase 3 trial

BeOne Medicines reported that its BTK inhibitor Brukinsa achieved a significant benefit in a Phase 3 trial for patients with mantle cell lymphoma who received the drug as first‑line therapy.

The study showed a 43% lower risk of disease progression or death compared with the standard chemo‑immunotherapy regimen, indicating a strong efficacy signal for Brukinsa in this setting.

The results position Brukinsa as a potential new frontline option for mantle cell lymphoma and could influence future treatment guidelines and regulatory considerations.